Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SABS

SABS - SAB Biotherapeutics, Inc. Stock Price, Fair Value and News

$4.41+0.13 (+3.04%)
Market Closed

36/100

SABS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

36/100

SABS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.23

Target 3M

$3.81

Target 6M

$3.58

SABS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SABS Price Action

Last 7 days

9.4%

Last 30 days

20.8%

Last 90 days

46.5%

Trailing 12 Months

113.0%

SABS RSI Chart

SABS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SABS Valuation

Market Cap

209.9M

Price/Earnings (Trailing)

11.2

Price/Sales (Trailing)

118.8

EV/EBITDA

-3.04

Price/Free Cashflow

-5.59

SABS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.23

Target 3M

$3.81

Target 6M

$3.58

SABS Fundamentals

SABS Revenue

Revenue (TTM)

1.3M

SABS Earnings

Earnings (TTM)

18.7M

Earnings Growth (Yr)

539.11%

Earnings Growth (Qtr)

549.32%

SABS Profitability

EBT Margin

-3445.78%

Return on Equity

11.35%

Return on Assets

10.22%

Free Cashflow Yield

-17.88%

SABS Investor Care

Shares Dilution (1Y)

415.82%

Diluted EPS (TTM)

-3.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.6M2.8M1.5M1.3M
202312.7M6.4M4.1M2.2M
202255.8M43.9M32.8M23.9M
202156.6M58.1M59.5M60.9M
20200029.3M55.2M
20190003.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About SAB Biotherapeutics, Inc.

SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
 CEO
 WEBSITEsabbiotherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES56

SAB Biotherapeutics, Inc. Frequently Asked Questions

SABS is the stock ticker symbol of SAB Biotherapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of SAB Biotherapeutics, Inc. is 209.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SABS's fair value in chart for subscribers.

The fair value guage provides a quick view whether SABS is over valued or under valued. Whether SAB Biotherapeutics, Inc. is cheap or expensive depends on the assumptions which impact SAB Biotherapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SABS.

As of Wed Jan 28 2026, SABS's PE ratio (Price to Earnings) is 11.2 and Price to Sales (PS) ratio is 118.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SABS PE ratio will change depending on the future growth rate expectations of investors.